GANX · Gain Therapeutics, Inc. · Documents
$1.26
-0.03 (-2.33%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”View the 10-Q filed Aug 11, 2026
Market Cap
$54.99M
Shares
43.64M
Volume · Oct 23
645.03K
Avg daily vol (3M)
503.57K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 10-Q | — | 2021-11-12 | 2021-09-30 | |
| 8-K | — | 2021-11-12 | — | |
| 8-K | — | 2021-10-20 | 2021-10-15 | |
| 10-Q | — | 2021-08-12 | 2021-06-30 | |
| 8-K | — | 2021-08-11 | — | |
| 10-Q | — | 2021-05-10 | 2021-03-31 | |
| 8-K | — | 2021-05-10 | — | |
| 8-K | — | 2021-05-04 | 2021-05-03 | |
| 8-K | — | 2021-03-22 | 2021-03-17 | |
| S-1/A | — | 2021-03-15 | — | |
| S-1/A | — | 2021-03-10 | — | |
| S-1 | — | 2021-02-19 | — |
Showing 101–112 of 112 filings